Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Inflammatory Bowel Disease During Childhood Linked to Higher Rates of Cancer and Early Death

A new Alimentary Pharmacology & Therapeutics study revealed an increased risk of cancer and early death in individuals who developed inflammatory bowel disease–including ulcerative colitis (UC) and Crohn’s disease (CD)—during childhood.

Thursday, May 9, 2019 12:01 am EDT

A new study revealed an increased risk of cancer and early death in individuals who developed inflammatory bowel disease–including ulcerative colitis (UC) and Crohn’s disease (CD)—during childhood.

For the Alimentary Pharmacology & Therapeutics study, researchers in Denmark and Finland followed 6,689 patients diagnosed with UC or CD before 18 years of age. Over a median follow-up of 9.6 years (when patients had a median age of 22.3 years), 72 patients developed cancer and 65 died. Most cancers were in the small or large intestine, but there were also cases of lymphomas and skin melanomas.

Patients diagnosed with UC during childhood had a 2.5-times higher risk of developing cancer and a 3.7-times higher risk of dying during follow-up compared with the general population. For CD, the risk was 2.6-times higher for cancer and 2.2-times higher for death compared with the general population. The main causes of death were cancer, suicide, and infections.

The findings stress the importance of cancer surveillance for young patients with UC or CD. Also, the increased risk of suicide found in the study points to the need to assess patients’ mental health. 

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15258 

About Journal 

Alimentary Pharmacology & Therapeutics is an international journal of gastroenterology and hepatology.

The journal accepts systematic reviews, meta-analyses, randomised controlled trials and original papers concerned with Gastroenterology and Hepatology.

AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses.

About Wiley

Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.

Multimedia Files:

Preview image

Contact:

Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com

Business Wire NewsHQsm